Birinapant - Medivir AB

Drug Profile

Birinapant - Medivir AB

Alternative Names: SMAC-mimetic; TL-32711

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Princeton University
  • Developer Medivir AB; National Cancer Institute (USA); University of Pennsylvania
  • Class Amides; Antineoplastics; Indoles; Pyrrolidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes; Ovarian cancer
  • Phase I/II Acute myeloid leukaemia; Hepatitis B; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Preclinical Legionella infections; Tuberculosis
  • Research HIV infections
  • No development reported Lymphoma; Pancreatic cancer

Most Recent Events

  • 18 Aug 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Refractory metastatic disease) in USA (IV) (NCT02587962)
  • 29 Dec 2016 Medivir acquires birinapant from TetraLogic Pharmaceuticals
  • 02 Nov 2016 Medivir plans a phase I trial for Solid tumours (Combination therapy, Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top